OVCAR3 with carboplatin resistance was more responsive to combinatorial treatment with carboplatin and APR-246, implying that reactivation of mutant p53 in OVCAR3 is required to re-sensitize ovarian cancer cells harboring R248Q mutation to chemotherapy to trigger programmed cell death (Supplementary Figs. 1 and 5). This evidence concerns the gene TP53 and ovarian carcinoma.